Roadmap: how OnCo keeps expanding and stays current

Every technology, target, drug, company, trial, and term has a URL and shows what links to it. That is what makes a hub rather than a list.

Editorial status was “shipped”, but records something links to is 2,909/4,436 (65.6%, target 95%). Claim it.

Clinicians, scientists and leaders per institution with specialisms, roles and papers at /people/.

Editorial status was “shipped”, but people with papers is 335/464 (72.2%, target 95%). Claim it.

Push structured facts to Wikidata and pull Wikipedia summaries, so the hub and the commons improve each other.

Patients, families, journalists, and investors should get the point in one sentence before the jargon.

Verified: tl;drs that are full sentences is 4,442/4,455 (99.7%, target 95%).

Let others build on the data: trial matchers, chatbots, dashboards. Published at /api/v1/.

An interactive force graph to navigate from a cancer to its targets to the drugs and the companies, visually.

Oncology changes weekly. Show when each fact was checked and what changed, like a package changelog.

Verified: records checked in the last 60 days is 4,455/4,455 (100%, target 90%).

Colour and badge every claim by evidence level so hype is visible at a glance.

Models, companies, datasets and two roadmaps mapped as first-class objects.

Hallmarks, metastasis, microenvironment, metabolism and dormancy as pathways, terms and ideas.

Sequencing, pathology, imaging, data, manufacturing and trial infrastructure that everything else depends on.

Translate hazard ratios and pCR rates into 'out of 100 people' pictograms.

Start with Spanish, Mandarin, Hindi, Portuguese, Arabic for the TL;DR layer only, where translation is cheap and value is high.

Select your cancer type(s) and see the technologies, drugs, trials, and ideas relevant to you.

Add PD-L1, HER2-low, BRCA, TROP2 status and get a narrower, more useful view. No data leaves the browser.

Per cancer and per stage, a printable list drawn from the state-of-art and pipeline sections.

From any drug or cancer page, live recruiting trials near a postcode.

Which institutions run the key trials for this cancer; how to get referred.

Supportive care, exercise oncology, financial toxicity, fertility, and late effects deserve first-class pages.

Nightly job pulls phase 2/3 trials for every drug and target in the corpus and flags new ones for review.

Editorial status was “shipped”, but products with a clinicaltrials.gov snapshot is 93/377 (24.7%, target 95%). Claim it.

History → current → emerging → speculative, with linked evidence. ADC, TROP2, radiopharma, cell therapy, imaging, early detection shipped.

Expected trial readouts, FDA PDUFA dates, and advisory committees (e.g., Galleri 23 Sep 2026) on one timeline.

Within a week of each congress, update the affected objects and publish a diff.

A section for drugs and ideas that failed (TIGIT, magrolimab, rovalpituzumab, iniparib) with what was learned. Failures are data.

Combinations that work, sequences that work, and cautions, each with rationale and evidence.

Hypotheses with a proposed test, so the community can argue, refine, and eventually see them tested.

For each drug class, the known escape routes and the drugs designed to close them.

Every ADC payload/linker with permeability, efflux susceptibility, and toxicity profile, cross-referenced to ADCs.

Ac-225, Lu-177, Pb-212 production capacity and suppliers, because supply gates the radiopharma roadmap.

Where the centres that matter are, ranked by a formula anyone can inspect and dispute.

Pull Nature Index and OpenAlex counts per institution for oncology journals; publish the query.

Which institutions led the pivotal trials in the corpus. A different signal from publication counts.

SWOG, NRG, Alliance, EORTC, BIG, GBG, JCOG: what they run and how to join.

NCI, CRUK, ERC, philanthropy: where the money goes by cancer and modality.

Like the Open Medical Registry: no claim without a URL and a date. Unknown is better than guessed.

Editorial status was “shipped”, but records with a primary source is 1,795/4,455 (40.3%, target 95%). Claim it.

Clinicians and scientists sign off on pages in their area; badge shows reviewer and date.

Editorial status was “shipped”, but records with a review badge is 0/4,436 (0%, target 10%). Claim it.

Advocacy groups (LBBC, BCRF, TNBC Foundation, PanCAN) review TL;DRs for clarity and tone.

One named reviewer per cancer and front.

Sponsors register readouts into the calendar.

Structured summaries within a week of each meeting.

Slides and quizzes per cancer and front.

Let readers back ideas and record when an organisation picks one up.

Every object is a TypeScript record; PRs with sources are the edit mechanism. CI validates links and references.

List missing objects and stale facts; recognise contributors who fill them.

The changelog is the newsletter. Zero extra editorial cost.

Verified organisations propose changes via /suggest/.

100 questions, a rubric, and a public leaderboard at /eval/.

Client-side index; works offline; no server.

Side-by-side of two drugs (e.g., sacituzumab vs Dato-DXd) or two technologies with the same fields.

One line of HTML to embed an OnCo object card in a blog, hospital site, or Wikipedia talk page.

Expose the corpus to AI assistants via Model Context Protocol so any chatbot can cite OnCo.

Each node links to its target page and the drugs against it.

Enter a molecular profile (mutations, IHC) and get the relevant targets, drugs, trials, and cautions in one printable view.

Curated sequences of pages: 'ADCs in 30 minutes', 'Understand your TNBC diagnosis', 'Radiopharma for investors'.

Patients bring printouts to appointments.

TNBC is first. Next: pancreatic, NSCLC, prostate, glioblastoma, each with a named expert reviewer.

Editorial status was “shipped”, but records with a review badge is 0/4,436 (0%, target 10%). Claim it.

Link out to and ingest from OncoKB, CIViC, ClinicalTrials.gov, ADCdb, NCI PDQ rather than duplicating them.

Maximise reuse; require attribution so improvements flow back.

Static export on Vercel; loads anywhere including low-bandwidth settings.

MedicalCondition, Drug, MedicalStudy markup so the hub is machine-readable to Google and AI crawlers.

Generated from the corpus: approvals, failures, roadmap progress, open problems. A yearly reference point.

Arms, N, endpoints, hazard ratios and confidence intervals on every trial.

Editorial status was “shipped”, but trials with structured outcomes is 346/401 (86.3%, target 95%). Claim it.

How common each target is in each cancer, sourced; matrix at /prevalence/.

Editorial status was “shipped”, but targets with sourced prevalence is 76/92 (82.6%, target 95%). Claim it.

All 31 cancers now carry standard of care by setting with guideline mapping, history, pipeline, open problems, and landmark trials with structured outcomes.

Verified: cancers with a deep dive is 64/64 (100%, target 95%).

Percent endpoints drawn as people, time endpoints as median bars.

Route, cycle, modifications, monitoring, with the label as source.

Grade 3+ rates by event, comparable across a class at /toxicity/.

Price where disclosed, reimbursement, assistance programmes, generics.

NCCN category and ESMO-MCBS grade on standard-of-care rows where sourced.

Filings, PDUFA dates, CRLs, label changes as dated events; browse at /regulatory/.

Step-by-step animated mechanism on product pages next to the molecule.

A reading level for a twelve-year-old, reviewed by advocates.

Editorial status was “shipped”, but records with a simple explanation is 875/4,455 (19.6%, target 80%). Claim it.

Spanish, Mandarin, Portuguese, Hindi, marked machine-assisted until reviewed.

Editorial status was “shipped”, but records with a tl;dr in all four languages is 448/4,455 (10.1%, target 50%). Claim it.

Choose questions, add your own, export one page.

Subscribe to a cancer, product, or target.

Cancer, stage, biomarkers, prior lines, country; nothing leaves the device.

What has been tried, what is next, and the cautions, at /navigator/.

Switch any page between TL;DR only and the full technical layer.

Logistics first: side effects to watch, when to call, practical support.

Glossary TL;DRs wherever a term appears.

Country and distance filters on live ClinicalTrials.gov results.

Any table state as a short URL pinned to a dashboard.

CSV, Parquet, Zenodo.

State-of-the-art panels and trial finders for hospital sites.

A PWA that caches the corpus.

Up to five items with a difference highlighter.

Cancers by targets by modalities at /pivot/.

The corpus as it stood in any year, at /timeline/.

Form-based queries over the graph at /query/.

Disclosed composite per trial and product; ranked at /evidence/.

Recomputed each build at /audit/.

Last edit, author, and diff from git on every page.

Editorial status was “shipped”, but records with git provenance is 2,003/4,455 (45%, target 95%). Claim it.

A badge for clarity and tone.

Editorial status was “shipped”, but records with a review badge is 0/4,436 (0%, target 10%). Claim it.

Superscripts and validation on unsourced numbers.

Weekly comparison against openFDA and ClinicalTrials.gov.

Probability ranges on speculative roadmap steps and ideas.

Every factual correction at /corrections/.

Shown next to every reviewer badge.

Whether a second trial confirmed the effect, on every trial.

ADC internalisation, CAR-T killing, radioligand decay, and more.

Editorial status was “shipped”, but technologies with a specific schematic is 114/348 (32.8%, target 80%). Claim it.

Each technology on a front page shows its schematic in motion.

Editorial status was “shipped”, but technologies with a specific schematic is 114/348 (32.8%, target 80%). Claim it.

Select a product and see the nodes it hits and the escape routes.

A clickable body map at /body/.

Drag, zoom, hydrogens, pharmacophore colours, drug-target complexes with binding pockets.

Verified: products with a molecule or an explained placeholder is 370/377 (98.1%, target 95%).

Light, dark, high contrast, skip link, focus rings.

Scroll-driven narrative on every roadmap.

Category matrix and animated escape-route maps per drug class at /resistance/.

Every linked object in every table explains itself on hover; headers and statuses too.

Type scale, surfaces, tables, header, home and footer made consistent and legible in light, dark and high contrast.

A systematic list of what is still missing for total information dominance, turned into work.

Track each bottleneck over time: is it easing or worsening, and which ideas are being tried.

Structures, logos, OpenAlex and GLOBOCAN refreshes are manual scripts; trials, papers and the fact check already run weekly in GitHub Actions. Put the rest on a schedule too.

A pull request may not lower a health gauge that is already above its target, so coverage only moves one way.

45 systemic constraints, each with sourced metrics, root causes, current efforts and a page at /bottlenecks/.

Verified: bottlenecks with ten or more ideas is 45/45 (100%, target 95%).

Ten waves of 100 ideas, each with a hypothesis, a test, who must act, cost and horizon; filterable at /ideas/.

Coverage metrics computed from the graph at build time, each with the worst offenders and the fix; an idea is only 'shipped' if its gauge agrees.

US, EU, UK, Japan, China and Australia compared product by product, gaps included.

Editorial status was “shipped”, but approved products with regional rows is 205/297 (69%, target 95%). Claim it.

Europe PMC feed and weekly trends on every drug, target, cancer and technology page, and at /papers/.

Editorial status was “shipped”, but records with a europe pmc snapshot is 546/881 (62%, target 95%). Claim it.

GLOBOCAN incidence per country and cancer with data gaps made explicit at /cases/.

Output, growth, trials, burden and funders per country at /countries/.

What the leading journals, regulators and news sources are saying this month at /pulse/.